What’s the current market cap for Ginkgo Bioworks stock?

Ginkgo Bioworks (DNA) has a market cap of $537m as of June 06, 2026.

What is the P/E ratio for Ginkgo Bioworks stock?

The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of June 06, 2026.

Does Ginkgo Bioworks stock pay dividends?

No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of June 06, 2026.

When is the next Ginkgo Bioworks dividend payment date?

Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Ginkgo Bioworks?

Ginkgo Bioworks (DNA) has a beta rating of 1.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Ginkgo Bioworks stock | $DNA Share Price

13:30

15:10

16:45

18:25

20:00

About Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Ticker

$DNA

Sector

Health

Primary listing

NYSE

Employees

485

Headquarters

Boston, United States

Website

www.ginkgo.bio

Ginkgo Bioworks Metrics

BasicAdvanced

$537m

-$5.36

1.78

Bulls say / Bears say

In Q2 2025, Cell Engineering revenue grew 8% year-over-year to $39 million, driven by strong demand from biopharma and government clients, underscoring the resilience of Ginkgo’s core platform. (Reuters)

Ginkgo met its $250 million annualized cost-reduction target ahead of schedule in Q2 2025, increasing operating leverage and supporting its aim for adjusted EBITDA breakeven by the end of 2026. (Reuters)

In April 2026, Ginkgo established an AI advisory board through a strategic partnership with ProQR, putting its autonomous lab platform at the leading edge of AI-driven drug discovery. (Reuters)

In Q3 2025, revenue dropped 56% year-over-year to $X, mainly due to last year’s non-cash revenue recognition and customer agreement cancellations, while adjusted EBITDA losses increased to $56 million, highlighting the segment’s volatility and softer demand. (Reuters)

In Q4 2025, total revenue declined 24% to $33 million and GAAP net loss reached $81 million, showing sustained top-line pressure and prompting Ginkgo to divest its Biosecurity segment in order to refocus on core operations. (prnewswire)

In Q1 2026, revenue fell 49% year-over-year to $19 million (or 37% when excluding a $7 million non-cash deferred revenue release), and GAAP net loss remained high at $76 million, reflecting significant program cutbacks and ongoing profitability challenges. (prnewswire)

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DNA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

In April 2026, Ginkgo established an AI advisory board through a strategic partnership with ProQR, putting its autonomous lab platform at the leading edge of AI-driven drug discovery. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.